Phare Bio, a biotech social venture leveraging artificial intelligence to accelerate antibiotic discovery and development, has announced a landmark strategic partnership with Basilea Pharmaceutica, a commercial-stage biopharmaceutical company focused on treating severe bacterial and fungal infections. The collaboration aims to jointly develop a next-generation broad-spectrum antibiotic designed to combat life-threatening infections caused by high-priority gram-negative pathogens—bacteria that pose a critical challenge due to rising resistance and limited treatment options. This partnership marks a historic milestone in antibiotic research: it integrates the patient-centered target product profile (TPP) directly into the AI-driven discovery process, ensuring that the resulting molecule is not only scientifically promising but also clinically relevant and development-ready. Crucially, the collaboration brings together Phare Bio’s advanced AI platform with Basilea’s proven expertise in clinical development and commercialization, creating a sustainable pathway from innovation to patient access. Under the agreement, Phare Bio will use its proprietary generative AI platform—specifically trained with drug-like properties—to design novel antibiotic candidates that meet the predefined TPP. Once promising molecules are identified, Basilea will take over clinical development and regulatory advancement. Phare Bio will be eligible for milestone payments tied to key development and regulatory successes, aligning incentives across both organizations. “This partnership is a watershed moment for the fight against antimicrobial resistance,” said Dr. Akhila Kosaraju, president and CEO of Phare Bio. “For the first time, we’re uniting AI-powered discovery with a committed industrial partner dedicated to advancing a viable antibiotic candidate through clinical development. This validates our hybrid model—combining nonprofit-driven innovation with private-sector collaboration—as a powerful, scalable solution to one of the most urgent public health crises of our era.” David Veitch, CEO of Basilea, added: “Partnering with Phare Bio reflects our ongoing commitment to pioneering innovation in antibiotic development. Their AI platform has the potential to dramatically accelerate the discovery of transformative antibacterial therapies. This collaboration strengthens our strategy to deliver differentiated, urgently needed treatments for patients facing life-threatening infections.” Phare Bio, founded in 2020, was established to confront the global crisis of antibiotic resistance by combining cutting-edge machine learning with expert scientific insight. Backed by The Audacious Project, Google.org, and ARPA-H, the company is pioneering a new model for collaborative, AI-driven drug discovery. More information is available at www.pharebio.org. Basilea Pharmaceutica, headquartered in Switzerland since 2000, is a commercial-stage biopharmaceutical company dedicated to developing innovative therapies for severe infections. It has successfully launched two hospital-only brands—Cresemba for invasive fungal infections and Zevtera for bacterial infections—and maintains a robust pipeline of preclinical and clinical anti-infective candidates. The company is listed on the SIX Swiss Exchange (SIX: BSLN). Visit basilea.com for more details.